Börsipäev 13. aprill
Kommentaari jätmiseks loo konto või logi sisse
-
Ostjad pole Ühendriikides suutnud juba mõnda aega tõestada, et neil oleks jõudu või huvi viia aktsiaid tagasi tippude juurde, piirdudes vaid päeva põhjadest noppimisega, mis jätab sentimendi ettevaatlikuks.S&P 500 indeks loovutas eile -0,4%, kui investorid jäid rohkete geopoliitiliste pealkirjade taustal ootama ettevõtete esimese kvartali tulemusi.
Majandustulemused aitasid Euroopas kergitada Stoxx 600 indeksi 0,2%ga 16 kuu kõrgeimale tasemele, olles sessiooni jooksul kaubelnud koguni 0,7% kõrgemal. Suurimateks tõusjateks olid indeksis Yara International +3.7%, Hays +3.4%, Zalando +3.3%, BTG +3.3%, Meggitt +3.0%. Tugevamalt said pihta Tesco -5.7%, ArcelorMittal -4.8%, Banco Popular Espanol -4.4%, Booker Group -4.1%, Rio Tinto -4.0%.
Jaapan on öösel olnud taaskord Aasia börsidest suurema surve all peamiselt jeeni tugevnemise tõttu USA dollari suhtes, mille taga oli eile õhtul Donald Trump, kes hindas Ühendriikide valuutat liiga tugevaks ning eelistab, et FED hoiaks intressimäärasid madalal tasemel. Nikkei 225 indeksi -0,7% langusele vastupidises suunas liikus Hiina Shanghai Composite (+0,1%), saades tuge märtsi kaubandusstatistikast. Import kasvas dollarites aastatagusega võrreldes 20,3% (oodati 15,5%) ning eksport paranes 16,4% (oodati 4,3%), mille taga on osaliselt suurenenud nõudlus aga ka toorainete hinnatõus.
Peamise tähelepanu all on täna Citigroup, JPMorgan ning Wells Fargo, kes avavad Ühendriikides esimese kvartali tulemuste hooaja. Majandusuudistes selguvad USA möödunud nädala esmased töötu abiraha taotlused ning Michigani ülikooli tarbijate kindlustunde indeks.
09.00 Saksamaa inflatsioon (märtsi lõplik)
09.00 Soome SKP indikaator (veebruar)
09.45 Prantsusmaa inflatsioon (märtsi lõplik)
15.30 USA tootjahinnaindeks (märts)
15.30 USA esmased töötu abiraha taotlused
17.00 USA Michigani ülikooli tarbijate kindlustunde indeks (aprill)
20.00 USA Baker Hughes aktiivsete nafta puurtornide arv (14. aprill) -
Soome majandus kasvas veebruaris aastatagusega võrreldes 3,0% pärast 3,7% tõusu jaanuaris (revideeriti 2,4% pealt positiivsemaks).
-
Algus on paljulubav
PNC prelim Q1 $1.96 vs $1.83 Capital IQ Consensus Estimate; revs $3.88 bln vs $3.79 bln Capital IQ Consensus Estimate
JPMorgan Chase prelim Q1 $1.65 vs $1.53 Capital IQ Consensus Estimate; revs $25.59 bln vs $24.40 bln Capital IQ Consensus Estimate -
Citigroup prelim Q1 $1.35 vs $1.24 Capital IQ Consensus Estimate; revs $18.12 bln vs $17.75 bln Capital IQ Consensus Estimate
Wells Fargo prelim Q1 $1.00 vs $0.96 Capital IQ Consensus Estimate; revs $22 bln vs $22.25 bln Capital IQ Consensus Estimate -
USA esmased töötu abiraha taotlused püsivad väga madalana, tootjahinnaindeks energiat ja kütust arvestamata kiirenes märtsis 0,1pp võrra 1,6%le, vähem kui oodatud 1,8%
US Initial Job Claims (WoW) 8-Apr: 234K (est 245K; rev prev 235K)
US PPI Ex-Food and Energy (YoY) Mar: 1.60% (est 1.80%; prev 1.50%) -
Gapping up
In reaction to strong earnings/guidance:
AAOI +23.7%, HBI +6.6%, (reports prelim results/updates guidance - CFO has decided to retire at the end of 2017)
APOG +1.6%, PNC +1.6%, JPM +0.5%, C +0.5%
Select AAOI related names/peers showing strength after AAOI earnings:
LITE +4.5%, FNSR +4.3%, OCLR +4.2%, ACIA +2.1%, INFN +2%, FN +1.8%, CIEN +1.6%
Select metals/mining stocks trading higher:
AU +2.3%, MTL +1.8%, MTL +1.8%, CDE +1.4%, AG +1.3%, GG +1%
Other news:
OCRX +41.2% (Ocera Therapeutics announces that data supporting the potential for OCR-002 in the treatment of NAFLD/NASH will be presented April 20)
EYES +32.8% (60 Minutes discusses how eye surgeons are making progress in restoring sight)
RLMD +22.2% (announces that the FDA has granted Fast Track designation for d-Methadone for the adjunctive treatment of major depressive disorder)
AEHR +4.9% (prices underwritten public offering of 3,846,154 shares of its common stock at $3.90/share)
ENTL +4.1% (receives 510(k) clearance from the FDA for use of its XprESS ENT Dilation System in patients with persistent Eustachian tube dysfunction)
CBIO +2.3% (light volume; announces closing of a $20.7 million underwritten public offering and full exercise of over-allotment option)
ACRX +1.9% (publishes two analyses of patient-controlled analgesia systems in Current Medical Research and Opinion analyzing iv, transdermal and ublingual patient-controlled analgesia systems)
INCY +1.5% (positive commentary on Mad Money)
DRYS +1.4% (after closing near highs up 25% on the yesterday)
BMY +1.1% (agrees to license BMS-986168 to Biogen (BIIB) and BMS-986089 to Roche)
Analyst comments:
VSTM +2.5% (initiated with Outperform ratings at Oppenheimer)
ADBE +1.2% (initiated with Buy ratings at Guggenheim)
SIX +0.9% (initiated with a Buy at SunTrust)
NS +0.5% (upgraded to Neutral from Underperform at Credit Suisse)
Gapping down
In reaction to disappointing earnings/guidance:
LEDS -12%, PIR -3.7%, INFY -3.7%
DTEA -2%, (also conducts its evaluation of the business under new leadership and develops its go-forward strategy to drive improved results, quarterly and annual guidance will not be provided)
WFC -1.2%, TSM -1.1%
Select EU financial related names showing weakness:
SAN -2.2%, BBVA -1.8%, HSBC -1.6%, ING -1.1%, RBS -1%, DB -0.9%, BCS -0.8%, CS -0.7%
Other news:
SRNE -33.9% (to offer shares of its common stock)
DMPI -25.1% (prices 2,769,232 shares of common stock and warrants to purchase an aggregate of 2,076,924 shares of common stock at $3.25 per share related warrant)
MOSY -22.7% (MoSys revises its operating plan, co to cut 60% of workforce, Board engaged an investment bank to act as its strategic financial advisor, and initiated a process to explore and review a range of strategic alternatives)
CHKE -4.6% (will file with the SEC for an automatic 15-day extension of the deadline for submitting its Annual Report on Form 10-K; co expects to file the Form 10-K on or before the extended deadline of April 28, 2017)
BBRY -1.6% (modestly pulling back following yesterday's strength)
AERI -1.3% (reported "positive rocket 4 six-month topline safety and efficacy results for Rhopressa")
ABT -1% (receives FDA warning letter relating to Fortify, Unify, Assura implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators, and the Merlin@home monitor)
Analyst comments:
WFT -2.5% (downgraded to Neutral from Buy at Goldman)
Briefing.com -
hard data on jätkuvalt kujunemas pehmemaks võrreldes küsitlustega...USA alusinflatsioon aeglustus märtsis 0,2pp võrra 2,0%le (oodati 2,3%)...
...ning märtsi jaemüük kasvas autosid ja kütust arvestamata MoM 0,1% vs prog 0,3%...
...mis võib tähendada Atlanta FEDi mudelis Q1 SKP 0,6% kasvu täiendavat kärpimist -
0,5% peale langetati pärast täna avaldatud märtsi jaemüüki
